Uncategorized

Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor

The first and only non-covalent (reversible)¬†BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the […]